Merck says its antiviral pill is less effective in a final analysis.

By BY REBECCA ROBBINS from NYT Science https://ift.tt/3cRWljD
via IFTTT Merck says its antiviral pill is less effective in a final analysis. The drug, molnupiravir, reduced the risk of hospitalization and death in high-risk Covid patients by 30 percent. An earlier analysis had found a 50 percent reduction. BY REBECCA ROBBINS https://ift.tt/3cRWljD https://ift.tt/3DYbPyC New York Times Science Coronavirus (2019-nCoV), Molnupiravir (Drug), Clinical Trials November 27, 2021 at 02:02AM